Scarica l'app Stockscreener
13.23
1.49%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.43
Aprire:
$13.56
Volume 24 ore:
2.54M
Relative Volume:
1.10
Capitalizzazione di mercato:
$11.02B
Reddito:
$3.97B
Utile/perdita netta:
$644.90M
Rapporto P/E:
16.97
EPS:
0.7794
Flusso di cassa netto:
$90.19M
1 W Prestazione:
-3.57%
1M Prestazione:
-0.08%
6M Prestazione:
-1.71%
1 anno Prestazione:
+0.38%
Intervallo 1D:
$13.21
$13.56
Intervallo di 1 settimana:
$13.21
$13.72
Portata 52W:
$12.77
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.23 | 11.02B | 3.97B | 644.90M | 90.19M | 0.7794 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-23 | Downgrade | Goldman | Neutral → Sell |
| 2025-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-12-19 | Downgrade | Nomura | Buy → Neutral |
| 2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
| 2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-30 | Iniziato | JP Morgan | Underweight |
| 2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Ripresa | BofA Securities | Neutral |
| 2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-09-18 | Aggiornamento | Investec | Sell → Hold |
| 2020-01-28 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-27 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2019-06-20 | Iniziato | Deutsche Bank | Hold |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
| 2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
| 2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
| 2017-07-28 | Downgrade | CLSA | Underperform → Sell |
| 2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
| 2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Dr. Reddy's Laboratories Ltd. Sponsored ADR Trade Ideas — LS:659157 - TradingView
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada - ChartMill
Dr. Reddy's Labs (ADR) stock (US2565981035): Why Google Discover changes matter more now - AD HOC NEWS
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - MSN
Dr Reddy’s (NYSE: RDY) Europe head reports 8,450 ADR-backed shares - Stock Titan
Dr. Reddy’s (NYSE: RDY) North America CEO reports 47,325 ADR shares - Stock Titan
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan - scanx.trade
Employee stock options add 3,675 Dr. Reddy’s (NYSE: RDY) shares - Stock Titan
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Benzinga
Dr. Reddy's Laboratories Ltd Stock Faces Analyst Downgrade Despite Strong Valuation—What European - AD HOC NEWS
Sapient Quality Select ETF Holdings - Quiver Quantitative
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital - TipRanks
Dr. Reddy’s (NYSE: RDY) allots 10,275 ESOP shares to employees - Stock Titan
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement - scanx.trade
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme - scanx.trade
Dr. Reddy’s Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
Mercurity Fintech Holding Inc ADR share price - Mint
Mitsubishi UFJ Financial Group Inc ADR share price - Mint
3 Generic Drug Stocks to Watch Despite Industry Headwinds - The Globe and Mail
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy - ChartMill
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action - scanx.trade
Dr. Reddy’s Stock Pops on US Launch Momentum: Buy the Breakout? - AD HOC NEWS
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes - scanx.trade
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital - TipRanks
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
US-India Trade Deal: Indian ADRs Jump Up To 6.75%; Sensex & Nifty Set For Rally - samco.in
Dr. Reddy’s Labs ADR earnings beat by $14.36, revenue topped estimates - Investing.com Australia
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y - Finviz
Dr. Reddy’s Strong Base Business, Aided by Partnerships and New Launches, Offsets North America Drag - Morningstar
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips By Investing.com - Investing.com India
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips - Investing.com
Infosys ADR stock jumps over 10% on Wall Street after IT major revises revenue guidance for FY2026 — Details here - Mint
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Dr. Reddy’s Labs ADR: Quiet Rally, Firm Fundamentals – Is RDY Still Undervalued? - AD HOC NEWS
HDFC Bank share price drops almost 4% in 2 days after Q3FY26 business update - Mint
Sarah Ketterer's PortfolioCauseway Capital Management - Gotrade
Infosys ADR Surges 15% Suddenly! Expert Feroze Azeez Reveals The Shocking Derivative Secret! - Whalesbook
Infosys trading: Infosys ADR 40% spike traced to data error, algo trading, says report - Business Today
What does Infosys ADR stock rally on the NYSE mean for Infosys shares on the NSE, BSE? - livemint.com
Infosys ADR stock jumps over 56% over strong volumes on US stock market today — Details here - livemint.com
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens - ChartMill
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.50%
1.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):